MO29872: Atezolizumab compared with chemotherapy in NSCLC
Research type
Research Study
Full title
A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.
IRAS ID
225049
Contact name
Siow-Ming Lee
Contact email
Sponsor organisation
F Hoffmann-La Roche Ltd
Eudract number
2015-004105-16
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
The purpose of this study is to compare the effects, good or bad, or atezolizumab compared to chemotherapy, on non-small lung cancer, to find out which is better.
In this study, patients will randomised to receive either atezolizumab or standard chemotherapy at a ratio of 2:1.
Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of non-small cell lung cancer. Atezolizumab is an antibody (a large, Y-shaped protein used by body’s immune system to identify and neutralise foreign objects such as bacteria, viruses and tumour cells) that affects the immune system by blocking the programmed death ligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in decreasing the body’s natural immune response to fight cancer. By blocking the PD-L1 pathway, atezolizumab may help the immune system stop or reverse the growth of tumours.
REC name
London - Brent Research Ethics Committee
REC reference
17/LO/1367
Date of REC Opinion
19 Sep 2017
REC opinion
Further Information Favourable Opinion